Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22816180 | 0.89 | S1PR1 (0.43) | S1PR1S1PR3KMO | |
| SCHEMBL22816288 | 0.85 | ALDH1A1 (0.50) | KMO | |
| SCHEMBL22816633 | 0.84 | S1PR1 (0.55) | S1PR1S1PR3KMOCSNK2A1 | |
| SCHEMBL22816443 | 0.78 | KMO (0.44) | KMO | |
| SCHEMBL22815610 | 0.78 | EIF4E (0.49) | — | |
| SCHEMBL22816286 | 0.76 | ALDH1A1 (0.50) | KMO | |
| SCHEMBL1294117 | 0.75 | S1PR1 (0.58) | S1PR1S1PR3KMOCSNK2A1 | |
| SCHEMBL22816176 | 0.73 | S1PR1 (0.43) | S1PR1S1PR3KMO | |
| SCHEMBL1293435 | 0.73 | S1PR1 (0.55) | S1PR1S1PR3KMOCSNK2A1 | |
| SCHEMBL1293503 | 0.72 | S1PR1 (0.73) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | S1PR1 2637/4885S1PR3 2971/4885KMO 248/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | S1PR1 2637/4885S1PR3 2971/4885KMO 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.